GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
Multiple Myeloma
DRUG: GR1803 injection
ORR evaluated by IRC, Sum of the proportions of patients with proven strict complete remission (sCR), complete remission (CR), very good partial remission (VGPR) and partial remission (PR), 2 years
ORR evaluated by investigator, Sum of the proportions of patients with proven strict complete remission (sCR), complete remission (CR), very good partial remission (VGPR) and partial remission (PR), 2 years|Progression-free survival (PFS) evaluated by IRC, Time from enrollment to tumor progression or death from any cause, 2 years|MRD negative rate, Proportion of subjects with at least 1 negative MRD after treatment, 2 years|AE, adverse event, 2 years
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.